Tavalisse: payments to doctors
Payments that named Tavalisse as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.4M
- Providers
- 8,399
- Transactions
- 30,441
- Average per transaction
- $209
The per-transaction average — $209 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,399 providers the average total is $757, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | $6,358,710 | 100.0% |